Anti-Human RET Recombinant Antibody (Y078) (CAT#: TAB-066MZ)

Figure 1 Anti-RET Y078 antibody internalizes and Y078 ADCs elicit potent in vitro cytotoxicity.

Internalization was assessed by incubating Y078 and RET-CHO cells for 30 minutes at either 4C or 37C, followed by detection of Y078 using anti-human IgG conjugated to AF488 in the presence or absence of anti-AF488 to block surface staining.

Nguyen, M., Miyakawa, S., Kato, J., Mori, T., Arai, T., Armanini, M., ... & Landes, G. (2015). Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. Clinical Cancer Research, 21(24), 5552-5562.

Figure 2 Representative images of immunohistochemical analysis of RET expression in MCF-7 tumors after treatment with Y078-DM1 (left) and Y078-DM4 (right).

The vast majority (n =6/7; 86%) of the Y078-DM4–treated tumors had pronounced necrotic areas as compared with size-matched tumors (n ¼ 0/6) treated with Y078-DM1. The expression of RET is limited to areas of cell viability and not in areas of necrosis.

Nguyen, M., Miyakawa, S., Kato, J., Mori, T., Arai, T., Armanini, M., ... & Landes, G. (2015). Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. Clinical Cancer Research, 21(24), 5552-5562.

Figure 3 Xenograft tumors with an average size of approximately 200 mm3 were treated weekly with vehicle and either Y078-DM1 (left) or Y078-DM4 (right), and their respective isotype controls ISO-DM1 and ISO-DM4, at the doses indicated

The MCF-7 and MCF-7/L-RET cell lines have approximately 30,000 and 120,000 receptors on their surface, respectively, as determined by quantitative flow cytometry (data not shown)

Nguyen, M., Miyakawa, S., Kato, J., Mori, T., Arai, T., Armanini, M., ... & Landes, G. (2015). Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma. Clinical Cancer Research, 21(24), 5552-5562.